guest ::
| Home > Publications database > Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. > print |
| Home > Publications database > Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. > print |
| 001 | 140855 | ||
| 005 | 20240229105118.0 | ||
| 024 | 7 | _ | |a 10.1038/s41375-018-0268-9 |2 doi |
| 024 | 7 | _ | |a pmid:30275528 |2 pmid |
| 024 | 7 | _ | |a 0887-6924 |2 ISSN |
| 024 | 7 | _ | |a 1476-5551 |2 ISSN |
| 024 | 7 | _ | |a altmetric:49080910 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2018-01610 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Braess, Jan |b 0 |
| 245 | _ | _ | |a Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. |
| 260 | _ | _ | |a London |c 2018 |b Springer Nature |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1552642497_30639 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Dose-dense induction with the S-HAM regimen was compared to standard double induction therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were centrally randomized (1:1) between S-HAM (2nd chemotherapy cycle starting on day 8 = 'dose-dense') and double induction with TAD-HAM or HAM(-HAM) (2nd cycle starting on day 21 = 'standard'). 387 evaluable patients were randomly assigned to S-HAM (N = 203) and to standard double induction (N = 184). The primary endpoint overall response rate (ORR) consisting of complete remission (CR) and incomplete remission (CRi) was not significantly different (P = 0.202) between S-HAM (77%) and double induction (72%). The median overall survival was 35 months after S-HAM and 25 months after double induction (P = 0.323). Duration of critical leukopenia was significantly reduced after S-HAM (median 29 days) versus double induction (median 44 days)-P < 0.001. This translated into a significantly shortened duration of hospitalization after S-HAM (median 37 days) as compared to standard induction (median 49 days)-P < 0.001. In conclusion, dose-dense induction therapy with the S-HAM regimen shows favorable trends but no significant differences in ORR and OS compared to standard double induction. S-HAM significantly shortens critical leukopenia and the duration of hospitalization by 2 weeks. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Amler, Susanne |b 1 |
| 700 | 1 | _ | |a Kreuzer, Karl-Anton |b 2 |
| 700 | 1 | _ | |a Spiekermann, Karsten |b 3 |
| 700 | 1 | _ | |a Lindemann, Hans Walter |b 4 |
| 700 | 1 | _ | |a Lengfelder, Eva |b 5 |
| 700 | 1 | _ | |a Graeven, Ullrich |b 6 |
| 700 | 1 | _ | |a Staib, Peter |b 7 |
| 700 | 1 | _ | |a Ludwig, Wolf-Dieter |b 8 |
| 700 | 1 | _ | |a Biersack, Harald |b 9 |
| 700 | 1 | _ | |a Ko, Yon-Dschun |b 10 |
| 700 | 1 | _ | |a Uppenkamp, Michael J |b 11 |
| 700 | 1 | _ | |a De Wit, Maike |b 12 |
| 700 | 1 | _ | |a Korsten, Stefan |b 13 |
| 700 | 1 | _ | |a Peceny, Rudolf |b 14 |
| 700 | 1 | _ | |a Gaska, Tobias |b 15 |
| 700 | 1 | _ | |a Schiel, Xaver |b 16 |
| 700 | 1 | _ | |a Behringer, Dirk M |b 17 |
| 700 | 1 | _ | |a Kiehl, Michael G |b 18 |
| 700 | 1 | _ | |a Zinngrebe, Bettina |b 19 |
| 700 | 1 | _ | |a Meckenstock, Gerald |b 20 |
| 700 | 1 | _ | |a Roemer, Eva |b 21 |
| 700 | 1 | _ | |a Medgenberg, Dirk |b 22 |
| 700 | 1 | _ | |a Spaeth-Schwalbe, Ernst |b 23 |
| 700 | 1 | _ | |a Massenkeil, Gero |b 24 |
| 700 | 1 | _ | |a Hindahl, Heidrun |b 25 |
| 700 | 1 | _ | |a Schwerdtfeger, Rainer |b 26 |
| 700 | 1 | _ | |a Trenn, Guido |b 27 |
| 700 | 1 | _ | |a Sauerland, Cristina |b 28 |
| 700 | 1 | _ | |a Koch, Raphael |b 29 |
| 700 | 1 | _ | |a Lablans, Martin |0 P:(DE-He78)e4ad7b4e684492de43cfcb12e5397439 |b 30 |u dkfz |
| 700 | 1 | _ | |a Faldum, Andreas |b 31 |
| 700 | 1 | _ | |a Görlich, Dennis |b 32 |
| 700 | 1 | _ | |a Bohlander, Stefan K |b 33 |
| 700 | 1 | _ | |a Schneider, Stephanie |b 34 |
| 700 | 1 | _ | |a Dufour, Annika |b 35 |
| 700 | 1 | _ | |a Buske, Christian |b 36 |
| 700 | 1 | _ | |a Fiegl, Michael |b 37 |
| 700 | 1 | _ | |a Subklewe, Marion |b 38 |
| 700 | 1 | _ | |a Braess, Birgit |b 39 |
| 700 | 1 | _ | |a Unterhalt, Michael |b 40 |
| 700 | 1 | _ | |a Baumgartner, Anja |b 41 |
| 700 | 1 | _ | |a Wörmann, Bernhard |b 42 |
| 700 | 1 | _ | |a Beelen, Dietrich |b 43 |
| 700 | 1 | _ | |a Hiddemann, Wolfgang |b 44 |
| 700 | 1 | _ | |a AML-CG |b 45 |e Collaboration Author |
| 773 | _ | _ | |a 10.1038/s41375-018-0268-9 |0 PERI:(DE-600)2008023-2 |n 12 |p 2558-2572 |t Leukemia |v 32 |y 2018 |x 1476-5551 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:140855 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 30 |6 P:(DE-He78)e4ad7b4e684492de43cfcb12e5397439 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |2 G:(DE-HGF)POF3-300 |v Translational cancer research |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b LEUKEMIA : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b LEUKEMIA : 2017 |
| 920 | 1 | _ | |0 I:(DE-He78)G230-20160331 |k G230 |l Medizinische Informatik in der Translationalen Onkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G230-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|